Neovacs S.A. (ALNEV.PA)
Paris · EUR · Healthcare · Biotechnology
€0.0924 (+2.67%) as of
Key statistics
- Market cap
- 14.70k
- Forward P/E
- 0.92
- EPS (TTM)
- -101,481.4531
- Dividend yield
- 0.00%
- 52-week range
- 0.0900 – 600.0000
- Beta
- -1,247.35
- Revenue (TTM)
- 199.27k
- Profit margin
- 0.00%
- Volume
- 78.56k
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suresnes, France
- Employees
- 16
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.